-
公开(公告)号：US20190119407A1
公开(公告)日：2019-04-25
申请号：US16062096
申请日：2016-12-14
Applicant: AMGEN INC.
Inventor： Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
公开(公告)号：US20170291929A1
公开(公告)日：2017-10-12
申请号：US15625891
申请日：2017-06-16
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Kenneth W. WALKER , Bryan LEMON
IPC: C07K14/475 , A61K39/00
CPC classification number: C07K14/475 , A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , A61K39/0005 , A61K2039/6056 , C07K14/495 , C07K14/51 , C07K2319/30
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20140302036A1
公开(公告)日：2014-10-09
申请号：US14203123
申请日：2014-03-10
Applicant: Amgen Inc.
Inventor： Hailing HSU , Ming ZHANG , Gunasekaran KANNAN , Frederick W. JACOBSEN , Wayne TSUJI
IPC: C07K16/24 , C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2827 , C07K16/2875 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/94 , C07K2318/10 , C07K2319/70
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Abstract translation: 本文描述了对BAFF和B7RP1特异性的双特异性蛋白质，编码这种蛋白质的核酸，制备此类蛋白质的方法以及这些蛋白质的用途。
-
公开(公告)号：US20140286898A1
公开(公告)日：2014-09-25
申请号：US14209699
申请日：2014-03-13
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Gunasekaran KANNAN , Li LI , Joshua T. PEARSON , Margaret KAROW
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20240368236A1
公开(公告)日：2024-11-07
申请号：US18639202
申请日：2024-04-18
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth William WALKER
IPC: C07K14/475
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
Patent Agency Ranking
公开(公告)号：US20240327486A1
公开(公告)日：2024-10-03
申请号：US18627761
申请日：2024-04-05
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20240327485A1
公开(公告)日：2024-10-03
申请号：US18627094
申请日：2024-04-04
Applicant: Amgen Inc.
Inventor： Marc Alain GAVIN , Gunasekaran KANNAN , Li Li , Joshua Thomas PEARSON , Margaret KAROW
CPC classification number: C07K14/55 , C07K16/00 , A61K38/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20230381276A1
公开(公告)日：2023-11-30
申请号：US18072959
申请日：2022-12-01
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. ALI , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Ian FOLTZ , Zhulun WANG , Darren BATES , Marissa MOCK , Shunsuke TAKENAKA
CPC classification number: A61K38/20 , C12N15/63 , A61P35/00 , C07K16/283 , C07K14/54 , A61K47/6849 , A61K47/6813 , C12N2740/10041
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US20210094997A1
公开(公告)日：2021-04-01
申请号：US17063566
申请日：2020-10-05
Applicant: Amgen Inc.
Inventor： Marc Alain GAVIN , Gunasekaran KANNAN , Li LI , Joshua Thomas PEARSON , Margaret KAROW
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20210047422A1
公开(公告)日：2021-02-18
申请号：US17005202
申请日：2020-08-27
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN , Ling LIU , Edward J. BELOUSKI , Cen XU
Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.023 seconds)
